Skip to main content

Fighting Neurodegeneration​ with New Tools

October 18, 2023
Imperial Ballroom
Relative to other highly prevalent diseases such as cancers or cardiovascular disease, companies seeking therapies for neurodegeneration have struggled with drug delivery and biomarker validation inside the brain.  Recent approvals of anti-amyloid therapies show one area of progress, with multiple other therapeutic approaches in clinical development. This session will feature companies describing new modalities and techniques for reaching diseased brain cells and measuring results to improve cognitive health for patients.
Susan Abushakra, Chief Medical Officer - Alzheon
Cory Nicholas, Co-Founder and CEO - Neurona Therapeutics
Robert Scannevin, Chief Scientific Officer - Verge Genomics
Ignacio Munoz-Sanjuan, Chief Executive Officer - Cajal Neuroscience
Nancy Stagliano, Chief Executive Officer and Board Chair - Neuron23